Angela G Fleischman

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
    Angela G Fleischman
    Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
    Blood 118:6392-8. 2011
  2. doi Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
    Angela G Fleischman
    Division of Hematology and Medical Oncology, Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Hematol 20:130-6. 2013
  3. pmc Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
    Julia E Maxson
    Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    N Engl J Med 368:1781-90. 2013
  4. pmc Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
    Anupriya Agarwal
    Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Blood 120:2658-68. 2012

Collaborators

  • Jeffrey W Tyner
  • Marc Loriaux
  • Thomas O'Hare
  • Richard T Maziarz
  • Anupriya Agarwal
  • Julia E Maxson
  • Michael W Deininger
  • Brian J Druker
  • Daniel Bottomly
  • Stephen T Oh
  • J Blake Pond
  • Jason Gotlib
  • Cristina E Tognon
  • Bill H Chang
  • Shannon K McWeeney
  • Beth Wilmot
  • Daniel A Pollyea
  • Basem Goueli
  • Christopher A Eide
  • Robert H Collins
  • Curtis L Petersen
  • Ryan Mackenzie
  • Samuel Luty
  • Randall L Woltjer

Detail Information

Publications4

  1. pmc TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
    Angela G Fleischman
    Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
    Blood 118:6392-8. 2011
    ....
  2. doi Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
    Angela G Fleischman
    Division of Hematology and Medical Oncology, Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Hematol 20:130-6. 2013
    ..A succinct yet comprehensive review of the biology of myeloproliferative neoplasms and therapeutic options with a focus on rational decision making for hematopoietic stem cell transplantation...
  3. pmc Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
    Julia E Maxson
    Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    N Engl J Med 368:1781-90. 2013
    ....
  4. pmc Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
    Anupriya Agarwal
    Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Blood 120:2658-68. 2012
    ..Beneficial effects of combining tyrosine kinase inhibitors with plerixafor may be observed in a situation of minimal residual disease, but caution is warranted when disease control is incomplete...